NCT03710603 2026-02-10PerseusEuropean Myeloma Network B.V.Phase 3 Active not recruiting709 enrolled 17 charts 1 FDA
NCT01415752 2025-04-08Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell LymphomaEastern Cooperative Oncology GroupPhase 2 Active not recruiting373 enrolled 14 charts
NCT01216683 2023-06-29Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaEastern Cooperative Oncology GroupPhase 2 Completed289 enrolled 34 charts
NCT00064038 2015-03-25S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple MyelomaSWOG Cancer Research NetworkPhase 3 Completed198 enrolled 6 charts